

Original article:

**SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF A NEW
DERIVATIVE OF THE MELDRUN ACID:
2,2-DIMETHYL-5-(4H-1,2,4-TRIAZOL-4-YLAMINOMETHYLENE)-
1,3-DIOXANE-4,6-DIONE (C₉H₁₀N₄O₄)**

Gillena M. M. Sampaio¹, Alexandre M. R. Teixeira^{1,2}, Henrique D. M. Coutinho^{*,1,3}
Diniz M. Sena Junior^{1,2}, Paulo T. C. Freire⁴, Ricardo R. F. Bento⁵, Luiz E. Silva⁶

¹ Mestrado em Bioprospecção Molecular

² Departamento de Física

³ Departamento de Química Biológica, Universidade Regional do Cariri, 63010-970, Brasil

⁴ Departamento de Física, Universidade Federal do Ceará, 60455-760, Brasil

⁵ Departamento de Física, Universidade Federal de Mato Grosso, 78060-900, Brasil

⁶ Setor Litoral - Universidade Federal do Paraná, Matinhos, 83260-000, Brasil

*Corresponding author: Henrique D. M. Coutinho. Departamento de Química Biológica, Universidade Regional do Cariri – URCA, Crato-CE, Brasil. Rua Cel. Antonio Luis 1161, Pimenta, 63105-000. Fone: +55(88)31021212; Fax +55(88) 31021291; E-mail: hdmcoutinho@gmail.com

ABSTRACT

The discovery of new substances with proven antimicrobial activity is the current study goal of various researchers. Usage of synthetic products has grown considerably in the past few years due to processing agility, and capability of going through previous chemical modifications in order to enhance its biological activity. Widespread careless use of antimicrobials has made the number of resistant microorganisms rise significantly, thus demanding more efficient drugs to fight them. One of these synthetic candidates for this purpose is the substance 2,2-Dimethyl-5-(4H-1,2,4-triazol-4-ylaminomethylene)-1,3-dioxane-4,6-dione (C₉H₁₀N₄O₄), aminomethylene derivative from Meldrum's acid. This substance, alone and in association with common antibiotics, were evaluated *in vitro* for antimicrobial activity, and had their minimum inhibitory concentration (MIC) towards *Staphylococcus aureus* ATCC 25923, *Escherichia coli* ATCC 10536 and *Pseudomonas aeruginosa* ATCC 15442, as well as multiresistant strains *Escherichia coli* 27, *Staphylococcus aureus* 358 and *Pseudomonas aeruginosa* 03 determined. The antimicrobial modulation action tests of the aminoglycosides with C₉H₁₀N₄O₄ were performed according to the microdilution method, and resulted in observation of a positive synergic effect.

Keywords: synthetic products, antimicrobial activity, resistant microorganisms, *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, aminoglycosides

INTRODUCTION

Staphylococcus aureus is a spherical bacterium from the Gram-positive cocci group, also characterized as being a facultative anaerobe pathogen. This microorganism is

easily found on the skin and mucous membranes of human beings, as well as in other mammals and birds. It can cause diseases that range from simple infections (pustules, furuncles and cellulitis) to more serious ones

(pneumonia, meningitis, endocarditis, toxic shock syndrome, septicemia, etc.) (Santos et al., 2007). It is an important etiological agent associated with acquired infections in the community and in hospitals, which became a paradigm of bacterial infections. Considered as one of the main human pathogens, it is notable for its high frequency and pathogenicity, which leads to diseases both in immunocompromised individuals and in healthy ones, and also for the easy intra-hospital dissemination associated to resistance to antibiotics (Coutinho et al., 2008, 2009).

The appearance of multiresistant *S. aureus* strains in the last few years, isolated even from hospital materials and equipments, constitutes a major problem to infection control and antimicrobial therapeutics (Araújo et al., 2000). Multiresistance in *S. aureus* results from the presence of plasmids which most frequently allows for multiresistance transfer, among other factors (Freitas, 2003).

Escherichia coli takes the form of a bacillus and belongs to the Enterobacteriaceae family, being aerobe and facultative anaerobe (Murray, 2004). It normally exists in animals (including humans) intestinal tract, and exert a benefic effect on the organism, suppressing proliferation of harmful bacteria and synthesizing a considerable portion of vitamins. Among *E. coli* strains, however, there is a group which is capable of causing diseases in humans, that is collectively called enteropathogenic *E. coli* (EEC) (Silva et al., 2003).

Pathogenic lineages of *E. coli* have been evidenced as a primary cause of urinary tract infections, neonatal meningitis, hospital-acquired septicemia, and enteritis in humans. Resistance to at least two different antibiotics classes is very common, which restricts the available therapeutic options (Schneider et al., 2009).

Pseudomonas aeruginosa is characterized by a Gram-negative rod, infecting a wide variety of plant and animal hosts (Wu et al., 2005). In humans, it is responsible for chronic lung infections affecting immunocompromised patients and also patients with

cystic fibrosis (Lyczak et al., 2000). *P. aeruginosa* is the third main cause of nosocomial infections (Bonomo and Szabo, 2006).

Widespread and careless use of antibiotics has led to a series of problems, among them, human ecology unbalance and microbial resistance, demanding a search for more efficient drugs to combat them. The development of any new antimicrobial drug is accompanied by microorganisms resistance, and their emergence is a threat to research advances (Lyczak et al., 2000). Due to the large raise of pathogenic microorganisms resistance to multiple drugs, there is a concern on finding new therapeutic alternatives (Oliveira et al., 2007). For patients, antimicrobial resistance augments morbidity, while for health institutions it corresponds to higher costs (Dancer, 2001).

According to Montanari (1995), molecular modification is the most used method to obtain new drugs. It consists, basically, in starting with a well characterized molecule, with known biological action, as a model or prototype, from which new compounds will be synthesized. The final product will be structurally similar, homolog, or analog, to the starting substance. Thus, the pharmaceutical industry is constantly developing research on the correlation of molecular structure and pharmacological activity of new synthetic products (Cechinel Filho and Yunes, 1998).

The synthesis of isolated pure substances has become a tool of great importance to the development of drugs with enhanced pharmacological properties, and nowadays the use of molecular modeling contributes markedly to the discovery of new drugs, which are safer and more efficient. Many heterocyclic derivatives of Meldrum acid (2,2-dimethyl-1,3-dioxane-4,6-dione) have been prepared and studied from the synthetic and structural point of view (Chen, 1991), but, however, its biological properties have not received the same attention.

In order to fill this gap, in this study we evaluate the antibacterial and the enhancement of antibiotic effect of 2,2-dimethyl-5-

(4H-1,2,4-triazol-4-ylaminomethylene)-1,3-dioxane-4,6-dione ($C_9H_{10}N_4O_4$) against standard and multiresistant (clinical origin) strains of *E. coli*, *S. aureus* and *P. aeruginosa*.

MATERIAL AND METHODS

Synthesis of compound

The search for a study to demonstrate the biological activity with 5-aminomethylene Meldrum's acid derivatives led to a patent in 1965 (Sterling Drug, 1966). In addition, different heterocyclic rings were condensed to the 5-methoxymethylene Meldrum's acid in order to evaluate their potential biological activity as antileishmanicidal, antitrypanosomal and antiviral (Silva, 2006). In this paper, we choose to synthesize the of compound 2,2-Dimethyl-5-(4H-1,2,4-triazol-4-ylaminomethylene)-1,3-dioxane-4,6-dione, $C_9H_{10}N_4O_4$, an aminomethylene derivative from Meldrum's acid in order to explore its biological application. The aminomethylene derivative can be obtained by condensation of an arylamine with 5-(methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione generated *in situ* from a reaction with trimethyl orthoformate (Cassis et al., 1985). A solution

of Meldrum acid (36 mmol) in thimethyl orthoformate (50 mL) was heated under reflux for 2 h, then the corresponding arylamine (30 mmol) was added. Reflux was kept for additional 30 minutes. The material thus formed was filtered and washed with methanol. The synthesis can be described by the scheme shown in Figure 1. The product of this synthesis was the compound 2,2-dimethyl-5-(4H-1,2,4-triazol-4-ylaminomethylene)-1,3-dioxane-4,6-dione, $C_9H_{10}N_4O_4$, a crystalline solid with melting point between 170 °C and 172 °C (Joussef et al., 2005).

Bacterial material

Standard and multiresistant lineages of *E. coli* (*E. coli* ATCC 10536 and *E. coli* 27), *S. aureus* (*S. aureus* ATCC 25923 and *S. aureus* 358) and (*P. aeruginosa* ATCC 15442 and *P. aeruginosa* 03) were assayed; the resistance profile is shown in Table 1. All lineages were kept in Heart Infusion Agar (HIA, Difco Laboratories Inc.). Before the essays were carried out, lineages were cultivated at 37 °C during 18 h in Brain Heart Infusion broth (BHI, Difco Laboratories Inc.).




Figure 1: Synthesis of the compound 2,2-Dimethyl-5-(4H-1,2,4-triazol-4-ylaminomethylene)-1,3-dioxane-4,6-dione, $C_9H_{10}N_4O_4$

Table 1: Resistance profile of microorganisms

Microorganism	Origin	Resistance Profile
<i>Escherichia coli</i> 27	Surgical wound	Ast; Ax; Amp; Ami; Amox; Ca; Can; Caz; Cip; Cfc; Cf; Clo; Im; Szt; Tet; Tob
<i>Staphylococcus aureus</i> 358	Surgical wound	Ami; But; Can; Gen; Neo; Net Oxa; Para; Sis; Tob;
<i>Pseudomonas aeruginosa</i> 03	Urine culture	Com; Ctz; Im; Cip; Ptz; Lev; Mer; Ami

Ast – Aztreonam; Ax – Amoxicillin; Amp – Ampicillin; Ami – Amikacin; Amox – Amoxicillin; But – Butirosina; Ca – Cefadroxil; Can – Kanamycin; Caz – Ceftazidime; Cip – Ciprofloxacin; Cfc – Cefaclor; Cf – Cephalothin; Clo – Chloramphenicol; Gen – Gentamicin; Im – Imipenem; Neo – Neomycin; Oxa – Oxacillin; Para – Paramomicina; Sis – Sisomicin; Szt – Sulfamethoxazole and Trimethoprim; Tet – Trimethoprim; Tob – Tobramycin; Com: Cefepime; Ctz: ceftazidima; Ptz: piperacilina-tazobactam; Lev: levofloxacin; Mer: meropenem

Antimicrobial activity assay

The initial solution was prepared by dissolving 0,01 g of the synthetic compound $C_9H_{10}N_4O_4$ in 1000 mL of DMSO (Merck), to result in a stock solution with concentration 10 mg/mL. This was diluted to 1024 $\mu\text{g/mL}$, and successive 1:2 dilutions with distilled water yielded concentrations from 512 to 0.5 $\mu\text{g/mL}$. The compound $C_9H_{10}N_4O_4$ was dissolved using dimethylsulfoxide (DMSO - Merck, Darmstadt, Alemanha) using the following proportions: 0.01 g of compound dissolved in 1 mL of DMSO, obtaining a solution with 10 mg/mL. This solution was diluted to 1024 $\mu\text{g/mL}$ and sequentially diluted with sterile water in a range varying from 512 to 0.5 $\mu\text{g/mL}$. The microorganisms employed in this study were provided by Instituto Nacional de Controle de Qualidade em Saúde (INCQS) from Fundação Oswaldo Cruz, Ministério da Saúde, Brasil. The MIC of the synthetic compound $C_9H_{10}N_4O_4$ was determined by the microdilution in broth method, using concentrations ranging from 512 to 8 $\mu\text{g/mL}$. Previously standardized bacterial suspensions were diluted in 1:10 proportion with BHI broth to yield a final concentration of 10^5 cells/mL (NCCLS, 2003). This method uses small volumes of medium (BHI 10 %) and sample ($C_9H_{10}N_4O_4$) distributed in cavities of sterile microplates. Sample was prepared in doubled concentration (1024 $\mu\text{g/mL}$) in relation to the defined initial concentration (512 $\mu\text{g/mL}$) with 100 μL volume, and then diluted 1:1 serially in BHI 10 %. Using 100 μL of culture medium per cavity, bacterial suspension was diluted at 1:10 proportion. Negative, positive (medium + microorganism), and inhibition controls were used with the culture medium, in concentrations ranging from 512 to 8 $\mu\text{g/mL}$. The filled plates were incubated at 35 °C (± 2 °C) for 24 h (Javadpour et al., 1996). A sodium resazurine indicator solution was prepared with sterile distilled water (0.01 % w/v) in order to determine the MIC of solutions toward standard bacterial lineages. After incubation, 20 μL of the indicator solution was added to

each cavity, and 1 hour later, under room temperature, results were read. A color change from blue to pink is due to resazurine reduction and indicates that bacterial growth has occurred (Palomino et al., 2002). The MIC can thus be verified, which is defined as the smallest drug concentration capable of inhibiting bacterial growth, evidenced by the unaltered blue color. The assessment of $C_9H_{10}N_4O_4$ as a possible modulator of antibiotic action was done by determining the MIC of antibiotics from the aminoglycoside group (amikacin, gentamicin e neomycin), with and without that substance, in sterile microplates. Aminoglycosides concentrations ranged from 2500 to 2.5 $\mu\text{g/ml}$. The $C_9H_{10}N_4O_4$ solution was added to BHI 10 % broth with subinhibitory concentrations, obtained after the MIC assessment, whereas for the modulation test, an 8 fold concentration reduction (MIC/8) was employed. Antibiotics solutions were prepared in doubled concentration (5000 $\mu\text{g/ml}$), relative to the initial one, with sterile distilled water. In each cavity of the sterile microplate there were 100 μL of the culture medium and the diluted (1:10) bacterial suspension. The controls used for MIC assessment of $C_9H_{10}N_4O_4$ were the same as the ones used for modulation tests (Sato et al., 2004). The filled microplates were incubated at 35 °C (± 2 °C) for 24 h, then reading was performed using the resazurine indicator solution, as previously described for the MIC assessment.

RESULTS AND DISCUSSION

Antimicrobials association is still studied due to the possibility of suppressing the appearance of resistant mutants, and producing an *in vivo* synergic effect. An attempt to maintain current antimicrobials active could be successful by combining them with other substances, presenting a therapeutic option to treat infections by *S. aureus* and other pathogens, regarding the growing cases of multiple resistance (Maia et al., 2009).

The MIC assessment test using the substance $C_9H_{10}N_4O_4$ indicated that the MIC is higher than 1024 $\mu\text{g/ml}$. According with

Houghton et al. (2007), this result indicates that the compound does not present a clinically relevant antibiotic activity.

In the modulation of antibiotic-activity test with aminoglycosides it was observed that, in relation to *Escherichia coli* 27, C₉H₁₀N₄O₄ presented a synergism with amikacin, reducing the inhibitory concentration from 19.5 to 4.9 µg/mL; whereas no noticeable effect was observed with gentamicin and neomycin. In relation to *Staphylococcus aureus* 358, C₉H₁₀N₄O₄ presented synergism with amikacin, gentamicin and neomycin, reducing the inhibitory concentration from 19.5 to 2.4 µg/mL, 9.8 to 2.4 µg/mL and 312.5 to 78.125 µg/ml, respectively. With respect to *Pseudomonas aeruginosa* 03, C₉H₁₀N₄O₄ showed synergy only with gentamicin, decreasing the inhibitory concentration from 156.2 to 39.1 µg/mL (Table 2). These results express the same mechanisms of action described by Bolla et al. (2011), that reports that these synergism is due the interaction with the bacterial cell membrane or with the lipopolysaccharide barrier (LPS), enhancing the antibiotic influx, increasing by this way the intracellular concentration, or inhibiting the antibiotic efflux due the activity as a blocker of efflux pump (BEP).

Table 2: MIC values (µg/mL) of aminoglycosides in the absence and presence of the compound C₉H₁₀N₄O₄ in multiresistant strains

	C ₉ H ₁₀ N ₄ O ₄ + antibiotic	antibiotic alone
<i>Escherichia coli</i> 27		
Amikacin	4.9 (S)	19.5 (I)
Gentamicin	4.9 (R)	4.9 (R)
Neomycin	1250 (R)	1250 (R)
<i>Staphylococcus aureus</i> 358		
Amikacin	2.4 (S)	19.5 (I)
Gentamicin	2.4 (S)	9.8 (R)
Neomycin	78.1 (R)	312.5 (R)
<i>Pseudomonas aeruginosa</i> 03		
Amikacin	78.1 (R)	78.1 (R)
Gentamicin	39.1 (R)	156.2 (R)
Neomycin	1250 (R)	1250 (R)

MIC – Minimum Inhibitory Concentration; S – Sensitivity;
I – intermediary resistance; R – Resistance.

Combination of antibiotics with laboratory synthesized isolated substances could serve as a therapeutic option for the treatment of infections caused by *S. aureus*, *E. coli*, *P. aeruginosa* and other pathogens, as well as an important approach to diminish multiple resistance.

Several compounds, as natural or synthetic, had demonstrated the capacity to modulate the antibiotic activity. Phenothiazines, in a general form, are capable to inhibit the bacterial efflux systems, enhancing the antibiotic activity. This activity was demonstrated by Chlorpromazine and thioridazine against several multiresistant bacteria (Amaral et al., 2010). As the phenothiazines, natural products can enhance the antibiotic activity inhibiting the bacterial efflux system, but also affecting the fluidity of the plasmatic membrane. Natural products as flavonoids (quercetin, isoquercetin, Rutin) (Veras et al., 2011; Araruna et al., 2012), alkaloids (Pilocarpine) (Araruna et al., 2012), terpenes (α-bisabolol) (Santos et al., 2011) had demonstrated this activity due the cited mechanisms. Both natural or synthetic compounds, modifying the antibiotic activity, can modify also the phenotype of the bacterial strains, reversing the resistant and intermediary phenotype to the sensitivity phenotype, as demonstrated by the compound C₉H₁₀N₄O₄ against the *E. coli*, *S. aureus* and *P. aeruginosa* strains.

CONCLUSIONS

According to the results obtained, it can be seen that the organic compound studied in this paper presents a modulator effect on antimicrobial activity, fulfilling expectations and providing a possible alternative in future therapeutics. In particular, it was shown that C₉H₁₀N₄O₄ presents antibiotic activity against *Escherichia coli*, *Staphylococcus aureus* and *Pseudomonas aeruginosa*.

ACKNOWLEDGEMENTS

We thank FUNCAP, FAPEMAT, CNPq for the financial support.

REFERENCES

- Amaral L, Martins A, Molnar J, Kristiansen JE, Martins M, Viveiros M et al. Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. *In vivo* 2010; 24:409-24.
- Araruna MKA, Brito SA, Morais-Braga MFB, Santos KKA, Souza TM, Leite TR et al. Evaluation of antibiotic & antibiotic modifying activity of pilocarpine & rutin. *Indian J Med Res* 2012;135:252-4.
- Araujo BAC, Oliveira AL, Santos Filho L. Isolamento de amostras multirresistentes de *Staphylococcus aureus* em estetoscópios usados no ambiente hospitalar. *RBAC* 2000;32:285-8.
- Bolla JM, Alibert-Franco S, Handzlik J, Chevalier J, Mahamoud A, Boyer G et al. Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria. *FEBS Lett* 2011;585:1682-90.
- Bonomo RA, Szabo D. Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. *Clin Infect Dis* 2006;43:S49-56.
- Cassis R, Tapia R, Valderrama JA. Synthesis of 4(1H)-quinolones by thermolysis of arylaminomethylene Meldrum's acid derivatives. *Synth Commun* 1985;15:125-9.
- Cechinel Filho V, Yunes RA. Estratégias para a obtenção de compostos farmacologicamente ativos a partir de produtos naturais. *Quím Nova* 1998;21:99-105.
- Chen BC. Meldrum's acid in organic synthesis. *Heterocycles* 1991;32:529-97.
- Coutinho HDM, Falcão-Silva VS, Gonçalves GF. Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers. *Int Arch Med* 2008;1:24.
- Coutinho HDM, Costa JG, Lima EO, Falcão-Silva VS, Siqueira-Júnior JP. Potentiating effect of *Mentha arvensis* and chlorpromazine in the resistance to aminoglycosides of methicillin-resistant *Staphylococcus aureus*. *In Vivo* 2009;23:287-9.
- Dancer SJ. The problem with cephalosporins. *J Antimicrob Chemother* 2001;48:463-78.
- Freitas DB. Atividade antimicrobiana de fluorquinolonas e ação sobre plasmídeos em amostras de *Staphylococcus aureus* humanas e bovinas. Dissertação de mestrado – CCEN/UFPB. João Pessoa, Brazil: UFPB 2003.
- Houghton PJ, Howes MJ, Lee CC, Steventon G. Uses and abuses of in vitro tests in ethnopharmacology: visualizing an elephant. *J Ethnopharmacol* 2007;110: 391-400.
- Javadpour MM, Juban MM, Lo WC, Bishop SM, Alberty JB, Cowell SM et al. De novo antimicrobial peptides with low mammalian cell toxicity. *J Med Chem* 1996;39:3107-13.
- Joussef AC, Silva LE, Bortoluzzi AJ, Foro S. 2,2-Dimethyl-5-[(1,2,4-triazin-3-ylamino)methylene]-1,3-dioxane-4,6-dione. *Acta Cryst E* 2005;61:O2873-4.
- Lyczak JB, Cannon CL, Pier CL. Establishment of *Pseudomonas aeruginosa* infection: lessons from a versatile opportunist. *Microbes Infect* 2000;2:1051-60.
- Maia RR, Pereira MSV, Albuquerque ACL, Pereira LF, Costa MRM. Estudo do efeito antimicrobiano do extrato da goiabeira (*Psidium guajava* Linn) sobre *Staphylococcus aureus* multiresistentes. *ACSA* 2009; 5:36-40.
- Montanari CA. Química medicinal: contribuição e perspectiva no desenvolvimento da farmacoterapia. *Quím Nova* 1995;18:56-64.
- Murray PR. *Microbiologia médica*, 4ª ed. São Paulo, Brazil: Elsevier, 2004.
- NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard – 6th ed. NCCLS document M7-A6. Wayne, PA: National Committee for Clinical Laboratory Standards, 2003.
- Oliveira RAG, Lima EO, Souza EL, Vieira WL, Freire KRL, Trajano VN et al. Interference of *Plectranthus amboinicus* (Lour.) Spreng essential oil on the anti-*Candida* activity of some clinically used antifungals. *Rev Bras Farmacogn* 2007;17:186-90.
- Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F. Resazurin microtiter assay plate: simple and unexpensive method for detection of drug resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2002;46:2720-2.
- Santos AL, Santos OD, Freitas CC, Ferreira BAL, Afonso IL, Rodrigues CR et al. *Staphylococcus aureus*: visitando uma cepa de importância hospitalar. *J Bras Pat Méd Lab* 2007;43:413-23.
- Santos NKA, Coutinho HDM, Viana GSB, Rodrigues FFG, Costa JGM. Chemical characterization and synergistic antibiotic activity of volatile compounds from the essential oil of *Vanillosmopsis arborea*. *Med Chem Res* 2011;20:637-41.

Sato Y, Shibata H, Arai T, Yamamoto A, Okimura Y, Arakaki N et al. Variation in synergistic activity by flavone and its related compounds on the increased susceptibility of various strains of methicillin – resistant *Staphylococcus aureus* to β – lactam antibiotics. *Int J Antimicrob Agents* 2004;24:28-35.

Schneider RN, Nadvorny A, Schmidt V. Perfil de resistência antimicrobiana de isolados de *Escherichia coli* obtidos de água superficiais e subterrâneas, em área de produção de suínos. *Biotemas* 2009;22:11-7.

Silva LE. Heterociclos aromáticos nitrogenados: síntese e potencial quimioterápico (doctoral thesis). Curitiba, Brazil: Universidade Federal do Paraná, 2006.

Silva N, Silveira NFA, Yokoya F, Okazaki MM. Ocorrência de *Escherichia coli* O157:H7 em vegetais e resistência aos agentes de desinfecção de verduras. *Ciênc Tecnol Aliment* 2003;23:167-73.

Sterling Drug, Inc. Aromatic amine derivatives and preparation. Patent, 464850, 1965. *Chem Abstract* 1966;1:147,759.

Veras HNH, Santos IJM, Santos ACB, Fernandes CN, Matias EFF, Leite GO et al. Comparative evaluation of antibiotic and antibiotic modifying activity of quercetin and isoquercetin in vitro. *Curr Top Nutraceut Res* 2011;9:25-30.

Wu M, Guina T, Brittnacher M, Nguyen H, Eng J, Miller SI. The *Pseudomonas aeruginosa* proteome during anaerobic growth. *J Bacteriol* 2005;187:8185-90.